Compare BTCS & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BTCS | RFL |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Real Estate |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.4M | 63.5M |
| IPO Year | 2008 | 2017 |
| Metric | BTCS | RFL |
|---|---|---|
| Price | $1.87 | $1.26 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 734.7K | 47.4K |
| Earning Date | 05-14-2026 | 06-10-2026 |
| Dividend Yield | ★ 2.62% | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,491,584.00 | $917,000.00 |
| Revenue This Year | $21.23 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 304.85 | 43.96 |
| 52 Week Low | $1.25 | $1.12 |
| 52 Week High | $8.49 | $3.19 |
| Indicator | BTCS | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 55.15 | 51.58 |
| Support Level | $1.46 | $1.16 |
| Resistance Level | $1.98 | $1.34 |
| Average True Range (ATR) | 0.13 | 0.07 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 64.81 | 50.15 |
BTCS Inc. ("BTCS" or the "Company"), short for Blockchain Technology Consensus Solutions, is a U.S.-based Ethereum-first blockchain technology company committed to driving scalable revenue and ETH accumulation through its hallmark strategy, the DeFi/TradFi Accretion Flywheel, an integrated approach to capital formation and blockchain infrastructure. By combining decentralized finance ("DeFi") and traditional finance ("TradFi") mechanisms with its blockchain infrastructure operations, comprising NodeOps (staking) and Builder+ (block building), BTCS offers one of the most sophisticated opportunities for leveraged ETH exposure, driven by scalable revenue generation and a yield-focused ETH accumulation strategy. Discover how BTCS offers operational and financial leveraged exposure to Ethereum through the public markets at www.btcs.com.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.